Resources Repository
-
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Test Performance | Health/Medicine | North America | Probability/Bayes | Technology Assessment | Infectious Diseases | Health Systems | Policy/Regulation | Government/Law | Global -
OrganizationWeb Portal 2024Center for the Evaluation of Value and Risk in Health (CEVR)
CEVR, the Center for the Evaluation of Value and Risk in Health, at Tufts Medical …
CEVR, the Center for the Evaluation of Value and Risk in Health, at Tufts Medical Center was established in 2005 and analyzes the benefits, risks and costs of strategies to improve health and health care. CEVR undertakes projects to determine the cost-effectiveness of health care interventions, including customized analyses for government agencies, private foundations and industry groups. CEVR has developed and maintains two internationally-known databases for health care stakeholders: the Cost-Effectiveness Analysis Registry and the National Coverage Determinations…
Health Outcomes | Health/Medicine | North America | Cost-Effectiveness Analysis | Technology Assessment | Health Systems